No connection

Search Results

INMD vs JNJ

INMD
InMode Ltd.
NEUTRAL
Price
$13.53
Market Cap
$857.2M
Sector
Healthcare
AI Confidence
85%
JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
INMD
9.46
JNJ
21.55
Forward P/E
INMD
8.84
JNJ
18.9
P/B Ratio
INMD
1.25
JNJ
7.03
P/S Ratio
INMD
2.31
JNJ
6.09
EV/EBITDA
INMD
3.6
JNJ
17.81

Profitability

Gross Margin
INMD
78.53%
JNJ
68.08%
Operating Margin
INMD
25.03%
JNJ
23.97%
Profit Margin
INMD
25.33%
JNJ
28.46%
ROE
INMD
13.53%
JNJ
35.03%
ROA
INMD
6.88%
JNJ
8.68%

Growth

Revenue Growth
INMD
6.1%
JNJ
9.1%
Earnings Growth
INMD
-63.5%
JNJ
48.6%

Financial Health

Debt/Equity
INMD
0.01
JNJ
0.6
Current Ratio
INMD
9.88
JNJ
1.03
Quick Ratio
INMD
8.55
JNJ
0.69

Dividends

Dividend Yield
INMD
--
JNJ
2.19%
Payout Ratio
INMD
0.0%
JNJ
46.6%

AI Verdict

INMD NEUTRAL

InMode presents a classic 'value trap' profile, characterized by a weak Piotroski F-Score of 3/9 and a completely bearish technical trend (0/100). While the company maintains an exceptional balance sheet with virtually no debt (Debt/Equity 0.01) and extreme liquidity (Current Ratio 9.88), these strengths are offset by a severe collapse in earnings growth (-63.50% YoY). The stock trades below its Graham Number ($18.63) but above its growth-based intrinsic value ($10.01), suggesting that while it is cheap on a book-value basis, its growth trajectory is deteriorating.

Strengths
Exceptional gross margins of 78.53%
Virtually debt-free balance sheet (Debt/Equity 0.01)
Extreme short-term liquidity with a Current Ratio of 9.88
Risks
Severe earnings contraction (-63.50% YoY)
Strongly bearish technical momentum (0/100 trend score)
Deteriorating fundamental health as indicated by Piotroski F-Score (3/9)
JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69

Compare Another Pair

INMD vs JNJ: Head-to-Head Comparison

This page compares InMode Ltd. (INMD) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile